NEW YORK, NY / ACCESS Newswire / March 17, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bernstein Liebhard LLP:Do you, or did you, own shares of Intellia Therapeutics, Inc.

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD despite promising trials.

Intellia Therapeutics (NASDAQ:NTLA) traded higher on Thursday as investors cheered pipeline updates the gene-editing biotech delivered with its better-than-expected Q4 2024 results. Cambridge, ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective dropped by equities researchers at Truist ...

THE LAWSUIT: A class action securities lawsuit was filed against Intellia Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...

Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing ...

Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox ...